Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure.

Abstract

AIMS:

To assess the effects of sodium-glucose co-transporter type 2 inhibitors on central blood pressure, an important determinant of cardiovascular events.

METHODS:

Canagliflozin, Empagliflozin or Luseogliflozin was given for 102 type 2 diabetic patients with hypertension and nephropathy. Central blood pressure was evaluated by radial tonometry. Clinical parameters were followed for 6 months.

RESULTS:

Three differing sodium-glucose co-transporter type 2 inhibitors similarly reduced brachial and central blood pressures, casual blood sugar, haemoglobin A1c, estimated glomerular filtration rate and albuminuria without significant changes in pulse rate and lipid profiles. Central systolic blood pressure was associated with the decreases in albuminuria by sodium-glucose co-transporter type 2 inhibitors.

CONCLUSION:

Comparable influences of various sodium-glucose co-transporter type 2 inhibitors on central blood pressure suggest class effects.

• Authors: Tsuneo Takenaka, Yoichi Ohno, Hiromichi Suzuki
• Journal: Diabetes & vascular disease research (Diab Vasc Dis Res) Vol. 15 Issue 2 Pg. 154-157 (03 2018) ISSN: 1752-8984 [Electronic] England
• PMID: 29168387 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Benzhydryl Compounds
• Blood Glucose
• Glucosides
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Sodium-Glucose Transporter 2
• Canagliflozin
• Sodium
• empagliflozin

Topics

• Adult
• Aged
• Benzhydryl Compounds (pharmacology)
• Blood Glucose (drug effects)
• Blood Pressure (drug effects)
• Canagliflozin (pharmacology)
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Diabetic Nephropathies (physiopathology)
• Female
• Glomerular Filtration Rate (drug effects)
• Glucosides (pharmacology)
• Glycated Hemoglobin (metabolism)
• Humans
• Hypertension (drug therapy)
• Hypoglycemic Agents (pharmacology)
• Kidney (physiopathology)
• Male
• Middle Aged
• Sodium (metabolism)
• Sodium-Glucose Transporter 2 (drug effects)